This bill mandates that the New Hampshire Department of Health and Human Services provide coverage for GLP-1 medications under the state Medicaid plan when deemed medically necessary by a licensed healthcare provider. The coverage criteria include patients with a Body Mass Index (BMI) of 30 kg/m² or higher (obesity) or a BMI of 27 kg/m² or higher with at least one weight-related comorbidity, such as Type 2 diabetes, hypertension, or cardiovascular disease. The bill introduces a new section, RSA 167:3-n, to the state Medicaid plan, which outlines these provisions.

Additionally, the bill requires the Department to submit any necessary amendments to the Centers for Medicare and Medicaid Services (CMS) by January 1, 2027, to facilitate the implementation of this coverage. The fiscal impact of the bill is significant, with estimated expenditures increasing to approximately $20.6 million by FY29, including both state and federal funds. The bill does not allocate new funding or positions but anticipates a substantial increase in Medicaid expenditures due to the rising utilization of GLP-1 medications for weight management.